We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sponsors of drugs to treat or prevent COVID-19 should focus on populations that are the hardest hit and least represented in clinical trials, including minorities and the elderly, according to a new FDA guidance released yesterday. Read More
The study also saw a greater portion of patients taking hydroxychloroquine with azithromycin experiencing cardiac arrest than those taking either medication alone. Read More
The Coalition for Epidemic Preparedness Innovations (CEPI) is giving Novavax an additional $384 million for development of its COVID-19 vaccine. Read More
The National Institutes of Health is sponsoring a clinical trial of Gilead Sciences’ antiviral remdesivir combined with Eli Lilly’s anti-inflammatory Olumiant (baricitinib) for treatment of COVID-19 infections. Read More
The partners expect that the therapy will be offered as a prophylactic for those returning to work and as a therapeutic for those who have been exposed to the coronavirus. Read More
California biotech firm Sorrento Therapeutics and New York City’s Mount Sinai Health System are teaming up to test and develop a triple antibody cocktail that could potentially treat or help prevent COVID-19. Read More